Rapaflo
Product Images NDC 54868-6173

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rapaflo (NDC 54868-6173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rapaflo (silodosin) 8mg X 30 Capsules (6173)

Label for RAPAFLO 8 mg capsules distributed by Physicians Total Care, Inc. The label includes the NDC 54868-6173 and indicates the manufacturing by Watson Labs, Inc. from Corona, CA. It features a barcode and space for lot number and expiration date.*

FDA Label Image

Silodosin Structural Formula. (Rapaflo Silodosin Capsules 1)

Chemical structure of the active ingredient in RAPAFLO, as shown in the image. This structural formula depicts the molecular composition typical for RAPAFLO's active compound.*

FDA Label Image

Figure 1 Mean (±sd) Silodosin Steady State Plasma Concentration-time Profile In Healthy Target-aged Subjects Following Silodosin 8 mg Once Daily With Food (Rapaflo Silodosin Capsules 2)

A line graph showing silodosin concentration (ng/mL) over time (hours). The graph depicts concentration peaking around 3-4 hours post-dose and then gradually declining with error bars representing variability at each time point.*

FDA Label Image

Figure 2 Mean Change From Baseline In Ipss Total Score By Treatment Group And Visit In Study 1 (Rapaflo Silodosin Capsules 3)

A line graph showing change from baseline in IPSS Total Score over Days for RAPAFLO 8 mg compared to placebo. The graph indicates a greater reduction in IPSS score with RAPAFLO 8 mg over time, with time points including baseline, days 3.5, 7, 14, 28, and 84/LOCF. Statistical significance (p ≤ 0.0001) is noted for the difference compared to placebo.*

FDA Label Image

Figure 3 Mean Change From Baseline In Ipss Total Score By Treatment Group And Visit In Study 2 (Rapaflo Silodosin Capsules 4)

A line graph comparing the change from baseline in IPSS total score over time (up to 84 days) between Placebo and RAPAFLO 8 mg groups. RAPAFLO 8 mg shows a greater and sustained decrease in IPSS total score compared to Placebo. Statistical significance is indicated for RAPAFLO at the final time point (p≤0.0001).*

FDA Label Image

Figure 4 Mean Change From Baseline In Qmax (ml/sec) By Treatment Group And Visit In Study 1 (Rapaflo Silodosin Capsules 5)

Line graph depicting change from baseline in Qmax (mL/sec) over multiple days for RAPAFLO 8 mg and placebo groups. The graph shows higher improvement in Qmax for RAPAFLO 8 mg, with data points on Days 1, 7, 14, 28, and 84/LOCF. Statistically significant differences are indicated for RAPAFLO 8 mg versus placebo.*

FDA Label Image

Figure 5 Mean Change From Baseline In Qmax (ml/sec) By Treatment Group And Visit In Study 2 (Rapaflo Silodosin Capsules 6)

A line graph comparing the change from baseline in Qmax (mL/sec) over time in days for RAPAFLO 8 mg versus placebo. Data points are shown for baseline, days 1, 7, 14, 28, and 84/LOCF. RAPAFLO consistently shows a higher increase in Qmax compared to placebo throughout the study period. Statistical significance is noted at p<0.05.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.